Intersect ENT

Intersect ENT Inc. (formerly Sinexus) is a medical device company pioneering novel therapies for Ear, Nose, and Throat surgeons to utilize in providing improved treatment for their patients. The company was founded in 2003 by Don Eaton and is headquartered in Menlo Park, California, United States.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT Announces Preliminary Revenue for Third Quarter of 2020

Intersect ENT Announces Preliminary Revenue for Third Quarter of 2020

MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT to Report Third Quarter 2020 Financial Results

Intersect ENT to Report Third Quarter 2020 Financial Results

MENLO PARK, Calif. & BERLIN--(BUSINESS WIRE)--Intersect ENT Closes Acquisition of Fiagon AG Medical Technologies

Intersect ENT Closes Acquisition of Fiagon AG Medical Technologies

MENLO PARK, Calif. and BERLIN--(BUSINESS WIRE)--Intersect ENT Announces Agreement to Acquire Fiagon AG Medical Technologies for €60 Million Paid Over Three Years

Intersect ENT Announces Agreement to Acquire Fiagon AG Medical Technologies for €60 Million Paid Over Three Years

Intersect ENT (XENT) partners with AllianceRx to expand the access to SINUVA Sinus Implant.

Intersect ENT, AllianceRx Execute Pharmacy-Services Agreement

MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT Announces Specialty Pharmacy Partnership Agreement with AllianceRx Walgreens Prime to Distribute SINUVA® Sinus Implant

Intersect ENT Announces Specialty Pharmacy Partnership Agreement with AllianceRx Walgreens Prime to Distribute SINUVA® Sinus Implant

Intersect ENT (XENT) reported earnings 30 days ago. What's next for the stock?

Why Is Intersect ENT (XENT) Down 1.2% Since Last Earnings Report?

Intersect ENT, Inc. (XENT) CEO Thomas West on Q2 2020 Results - Earnings Call Transcript

Although Intersect ENT's (XENT) Q2 sales are down year over year, it's stronger than expected, led by the return of sinus surgery procedures using PROPEL.

Intersect ENT (XENT) Q2 Loss Widens, Revenues Beat Estimates

MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT Reports Second Quarter 2020 Financial Results

Intersect ENT Reports Second Quarter 2020 Financial Results

MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT to Report Second Quarter 2020 Financial Results

Intersect ENT to Report Second Quarter 2020 Financial Results

Investors need to pay close attention to Intersect ENT (XENT) stock based on the movements in the options market lately.

Implied Volatility Surging for Intersect ENT (XENT) Stock Options

Allstate

Medtronic

National General Holdings

During a period like the COVID-19 pandemic, there are at least two reasons to find an acquisition or a merger.

2 Big Mergers: One a $4 Billion Cash Deal, the Other Still in the Rumor Mill 

Shares of Intersect ENT Inc (NASDAQ: XENT), a manufacturer of sinus implants for delivering targeted therapy to the ear, nose and throat, are skyrocketing to their best level since mid-March following a buyout rumor.

Intersect ENT Rips Higher On Medtronic M&A Rumor

Investors reacted enthusiastically to a reported acquisition offer from Medtronic.

Why Intersect ENT Stock Is Skyrocketing Today

Sources confirmed late on Tuesday that Medtronic (NYSE: MDT) is interested in acquiring Intersect ENT (NASDAQ: XENT) and has already forwarded its offer to the medical device manufacturer. The bid, as per the sources, is now under review by Intersect’s board of directors in collaboration with the company’s advisers.

Medtronic shows interest in acquiring smaller rival Intersect ENT

MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to transforming care for patients with ear, nose and throat conditions, today announced the results of a United Kingdom-based independent analysis measuring costs and patient outcomes of the PROPEL steroid releasing sinus implant compared to a non-drug-eluting spacer following endoscopic sinus surgery for patients with chronic sinusitis. The study demonstrated that the use of PROPEL following surgery re

Intersect ENT Announces Independent Analysis in UK Confirming Cost Effectiveness of PROPEL® Steroid Releasing Sinus Implant Following Sinus Surgery for Chronic Sinusitis

This latest reimbursement development broadens Intersect ENT's (XENT) already-extensive customer base to a significant extent.

Intersect ENT's Sinuva Adoption to Rise on New C-Code by CMS

Intersect ENT (XENT) performs disappointingly in the first quarter of 2020 due to the coronavirus crisis.

Intersect ENT (XENT) Reports Wider-Than-Expected Q1 Loss

Intersect ENT, Inc. (XENT) CEO Tom West on Q1 2020 Results - Earnings Call Transcript

Intersect ENT (XENT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Intersect ENT (XENT) Q1 Earnings Expected to Decline

Intersect ENT, Inc. (XENT) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

Moving Average Crossover Alert: Intersect ENT

Intersect (XENT) expects the impact of the coronavirus pandemic to substantially dampen revenues in the second quarter as well.

Intersect Posts Preliminary Q1 Results, Withdraws '20 View

Intersect ENT (XENT) Down 49.5% Since Last Earnings Report: Can It Rebound?

Intersect ENT (XENT) registers dull Propel performance on poor unit sales in Q4.

News for Intersect ENT Stock (XENT)